CO5190700A1 - IMIDAZO COMPOUNDS [1,5-a] -PRESS [3,2-e] PIRAZONAS, PROCEDURE FOR PREPARATION AND MEDICINES CONTAINING THEM. . . . . - Google Patents
IMIDAZO COMPOUNDS [1,5-a] -PRESS [3,2-e] PIRAZONAS, PROCEDURE FOR PREPARATION AND MEDICINES CONTAINING THEM. . . . .Info
- Publication number
- CO5190700A1 CO5190700A1 CO00002747A CO00002747A CO5190700A1 CO 5190700 A1 CO5190700 A1 CO 5190700A1 CO 00002747 A CO00002747 A CO 00002747A CO 00002747 A CO00002747 A CO 00002747A CO 5190700 A1 CO5190700 A1 CO 5190700A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- aryl
- several times
- once
- unsaturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Imidazo [1, 5 - a] - pirido [3,2 - e] - pirazinonas de la fórmula 1<EMI FILE="00002747_1" ID="1" IMF=JPEG >dondeA es O,R1, R2 , R3 pueden ser iguales o diferentes y pueden significar hidrógeno, así como - C1-8 - alquilo, de cadena recta o de cadena ramificada, llegado el caso, sustituido una o varias veces con - OH, - SH, - NH2, - NHC1-6 - alquilo, -N (C1-6 - alquilo)2, - NHC6-14 arilo, - N(C6-14arilo)2, - N (C1-6 alquil) (C6-14 arilo), - NO2, - CN, - COOH, - COOC1-5 alquilo, - (C = O) C1-5 alquilo, - F, - CI, - Br, - I, 0 - C1-6 - alquilo, - O - C6-14 - arilo- S - C1-6 -alquilo, - S - C6-14, arilo, - OSO2C1-6 alquilo, - OSO2C6-14 arilo, carbociclos saturados mono, bi o tricíclicos o insaturados una o varias veces con 3 a 14 miembros del anillo, heterociclos saturados mono, bi tricíclicos o insaturados una o varias veces con 5 a 15 miembros del anillo y 1 a 6 heteroátomos, que son preferentemente N, O y S, -C2-8 - alquenilo, insaturado una o varias veces, de cadena recta o de cadena ramificada, llegado el caso, sustituido una o varias veces con - OH, - SH, - NH2, - NHC1-6 -alquilo, - N (C1-6 - alquilo)2, - NHC6-14 arilo, - N (C6-14 arilo)2, - N(C1-6 alquil)(C6-14 arilo), - NO2, - CN, - COOH, - COOC1-5 alquilo, - (C = O) C1-5 alquilo, - F, - CI, - Br, - I, - O - C1-6 -alquilo, - O - C6-14 - arilo, - S - C1-6 - alquilo, - S - C6-14 arilo, -OSO2C1-6 alquilo, - OSO2C6-14 arilo, carbociclos saturados mono, bi o tricíclicos o insaturados una o varias veces con 3 a 14 miembros del anillo, heterociclos saturados mono, bi o tricíclicos o insaturados una o varias veces con 5 a 15 miembros del anillo y 1 a 6 heteroátomos, que preferentemente son N, O y S,C2-8 - alquinilo, insaturado una o varias veces, de cadena recta o de cadena ramificada, llegado el caso, sustituido una o varias veces con - OH, - SH, - NH2, - NHC1-6 - alquilo, - N (C1 -6 - alquilo)2, - NHC6-14 arilo, - N (C6-14 arilo)2, - N (C1-6 alquil) (C6-14 arilo), - NO2, - CN, - COOH, - COOC-1-5 alquilo, - (C = O) C1-5 alquilo, - F, - CI, - Br, - I, - O - C1-6 - alquilo, - O - C6-14 - arilo, - S - C1-6 - alquilo, - S - C6-14 arilo, -OSO2C1-6 alquilo, -OSO2C6-14 arilo, carbociclos saturados mono, bi o tricílicos o insaturados una o varias veces con 3 a 14 miembros del anillo, - 2 -heterociclos saturados mono, bi o tricílicos o insaturados una o varias veces con 5 a 15 miembros del anillo y 1 a 6 heteroátomos, que son preferentemente N, O y S,- carbociclos saturados mono, bi o tricíclicos o insaturados una o varias veces con 3 a 14 miembros del anillo, llegado el caso, sustituido una o varias veces con -OH, -SH, - NH2, - NHC1-6 - alquilo, - N (C1-6 - alquilo)2, - NHC6-14 arilo, - N (C6-14 arilo)2, - N (C1-6 alquil) (C6-14 arilo), - NO2, - CN, - COOH, - COOC1-5 alquilo, - (C = O) C1-5 alquilo, - F, CI, - Br, - I, - O - C1-6 - alquilo, - O - C6-14 - arilo, - S - C1-6 - alquilo, - S - C6-14 arilo, - OSO2C1-6 alquilo, - OSO2C6-14 arilo, - heterociclos saturados mono, bi o tricíclicos o insaturados una o varias veces con 5 a 15 miembros del anillo y 1 a 6 heteroátomos, que son preferentemente N, O y S,llegado el caso, sustituido una o varias veces con - OH, - SH, - NH2, - NHC1-6 - alquilo, - N (C1-6 -alquilo)2, - NHC6-14 aril, - N (C6-14 arilo)2, - N (C1-6 alquil) (C6-14 arilo), - NO2 - CN, - COOH, -COOC1-5 alquilo, - (C = O) C1-5 alquilo, - F, - CI, - Br, - I, - O - C1-6 - alquilo, - O - C6-14 - arilo, - S - C1-6 - alquilo, - S - C6-14 arilo, - OSO2C1-6 alquilo, - OSO2C6-14 arilo.-Procedimiento para preparar compuestos según la fórmula 1 conforme a las reivindicaciones 1 a 4 así como otros compuestos según fórmula 1, donde A es NH, R1, R2, R3 pueden ser iguales o diferentes y poseen nuevamente el significado descripto en la reivindicación 1, caracterizado por que se transforman las 3 - aminopiridina de fórmula 2 con idéntico significado de A, R1, R2 y R3<EMI FILE="00002747_2" ID="2" IMF=JPEG >en un solvente orgánico en presencia de un ácido con un cianato y porque las ureas formadas de fórmula 3 con idéntico significado de A, R1, R2 y R3<EMI FILE="00002747_3" ID="3" IMF=JPEG >se calientan a continuación en un solvente orgánico de manera tal que resulta una ciclización para formar los compuestos de fórmula 1 conformes a la invención.Imidazo [1, 5 - a] - pyrido [3,2 - e] - pyrazinones of the formula 1 <EMI FILE = "00002747_1" ID = "1" IMF = JPEG> where A is O, R1, R2, R3 can be same or different and may mean hydrogen, as well as - C1-8 -alkyl, straight chain or branched chain, if necessary, substituted once or several times with - OH, - SH, - NH2, - NHC1-6 - alkyl , -N (C1-6-alkyl) 2, - NHC6-14 aryl, - N (C6-14aryl) 2, - N (C1-6 alkyl) (C6-14 aryl), - NO2, - CN, - COOH , - COOC1-5 alkyl, - (C = O) C1-5 alkyl, - F, - CI, - Br, - I, 0 - C1-6 - alkyl, - O - C6-14 - aryl- S-C1 -6 -alkyl, - S - C6-14, aryl, - OSO2C1-6 alkyl, - OSO2C6-14 aryl, mono, bi or tricyclic or unsaturated saturated carbocycles one or more times with 3 to 14 ring members, mono saturated heterocycles , bi tricyclic or unsaturated once or several times with 5 to 15 ring members and 1 to 6 heteroatoms, which are preferably N, O and S, -C2-8-alkenyl, unsaturated once or several times, straight chain or cad branched, if necessary, substituted once or several times with - OH, - SH, - NH2, - NHC1-6 -alkyl, - N (C1-6-alkyl) 2, - NHC6-14 aryl, - N (C6 -14 aryl) 2, - N (C1-6 alkyl) (C6-14 aryl), - NO2, - CN, - COOH, - COOC1-5 alkyl, - (C = O) C1-5 alkyl, - F, - CI, - Br, - I, - O - C1-6 -alkyl, - O - C6-14 - aryl, - S - C1-6 - alkyl, - S - C6-14 aryl, -OSO2C1-6 alkyl, - OSO2C6-14 aryl, mono, bi or tricyclic or unsaturated saturated carbocycles once or several times with 3 to 14 ring members, mono, bi or tricyclic or unsaturated saturated heterocycles once or several times with 5 to 15 ring members and 1 to 6 heteroatoms, which are preferably N, O and S, C2-8-alkynyl, unsaturated once or several times, straight chain or branched chain, if necessary, substituted once or several times with - OH, - SH, - NH2 , - NHC1-6-alkyl, - N (C1-6-alkyl) 2, - NHC6-14 aryl, - N (C6-14 aryl) 2, - N (C1-6 alkyl) (C6-14 aryl), - NO2, - CN, - COOH, - COOC-1-5 alkyl, - (C = O) C1-5 alkyl, - F, - CI, - Br, - I, - O - C1-6 - alkyl, - O - C6-14 - aryl, - S - C1-6 - alkyl, - S - C6-14 aryl, -OSO2C1-6 alkyl, -OSO2C6-14 aryl, mono, bi or tricyclic or unsaturated saturated carbocycles with 3 to 14 ring members, - 2-saturated mono, bi or tricyclic or unsaturated heterocycles once or several times with 5 to 15 ring members and 1 to 6 heteroatoms, which are preferably N, O and S, - saturated mono, bi or tricyclic or unsaturated carbocycles once or several times with 3 to 14 ring members, the case, substituted once or several times with -OH, -SH, - NH2, - NHC1-6 -alkyl, - N (C1-6 -alkyl) 2, - NHC6-14 aryl, - N (C6-14 aryl) 2 , - N (C1-6 alkyl) (C6-14 aryl), - NO2, - CN, - COOH, - COOC1-5 alkyl, - (C = O) C1-5 alkyl, - F, CI, - Br, - I, - O - C1-6 - alkyl, - O - C6-14 - aryl, - S - C1-6 - alkyl, - S - C6-14 aryl, - OSO2C1-6 alkyl, - OSO2C6-14 aryl, - mono, bi or tricyclic or insat saturated heterocycles once or several times with 5 to 15 ring members and 1 to 6 heteroatoms, which are preferably N, O and S, if necessary, substituted once or several times with - OH, - SH, - NH2, - NHC1-6 - alkyl, - N (C1-6 -alkyl) 2, - NHC6-14 aryl, - N (C6-14 aryl) 2, - N (C1-6 alkyl) (C6-14 aryl), - NO2 - CN, - COOH, -COOC1-5 alkyl, - (C = O) C1-5 alkyl, - F, - CI, - Br, - I, - O - C1-6 - alkyl, - O - C6-14 - aryl, - S - C1-6 - alkyl, - S - C6-14 aryl, - OSO2C1-6 alkyl, - OSO2C6-14 aryl.-Process for preparing compounds according to formula 1 according to claims 1 to 4 as well as other compounds according to formula 1, wherein A is NH, R1, R2, R3 can be the same or different and again have the meaning described in claim 1, characterized in that the 3-aminopyridine of formula 2 is transformed with the same meaning of A, R1, R2 and R3 <EMI FILE = "00002747_2" ID = "2" IMF = JPEG> in an organic solvent in the presence of an acid with a cyanate and by that the ureas formed of formula 3 with the same meaning of A, R1, R2 and R3 <EMI FILE = "00002747_3" ID = "3" IMF = JPEG> are then heated in an organic solvent in such a way that cyclization results forming the compounds of formula 1 according to the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1999102082 DE19902082A1 (en) | 1999-01-20 | 1999-01-20 | New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction |
| DE1999161302 DE19961302A1 (en) | 1999-12-18 | 1999-12-18 | Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5190700A1 true CO5190700A1 (en) | 2002-08-29 |
Family
ID=26051406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00002747A CO5190700A1 (en) | 1999-01-20 | 2000-01-19 | IMIDAZO COMPOUNDS [1,5-a] -PRESS [3,2-e] PIRAZONAS, PROCEDURE FOR PREPARATION AND MEDICINES CONTAINING THEM. . . . . |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1144410A2 (en) |
| JP (1) | JP2002535330A (en) |
| KR (1) | KR20010101603A (en) |
| CN (1) | CN1344268A (en) |
| AR (1) | AR022318A1 (en) |
| AU (1) | AU2291200A (en) |
| BG (1) | BG105714A (en) |
| BR (1) | BR0007613A (en) |
| CA (1) | CA2296224A1 (en) |
| CO (1) | CO5190700A1 (en) |
| CZ (1) | CZ20012627A3 (en) |
| EA (1) | EA200100792A1 (en) |
| EE (1) | EE200100377A (en) |
| HU (1) | HUP0105132A3 (en) |
| ID (1) | ID29790A (en) |
| IL (1) | IL144156A0 (en) |
| IS (1) | IS5987A (en) |
| LT (1) | LT2001078A (en) |
| LV (1) | LV12793B (en) |
| NO (1) | NO20013334D0 (en) |
| SK (1) | SK10322001A3 (en) |
| TR (1) | TR200102121T2 (en) |
| WO (1) | WO2000043392A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| WO2003051346A2 (en) * | 2001-12-17 | 2003-06-26 | Altana Pharma Ag | Use of selective pde5 inhibitors for treating partial and global respiratory failure |
| FR2835741B1 (en) * | 2002-02-12 | 2006-05-05 | Oreal | NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS |
| US6916345B2 (en) | 2002-02-12 | 2005-07-12 | L'oreal S.A. | 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres |
| DE10325813B4 (en) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxis and / or therapy in portal hypertension |
| JP5070052B2 (en) * | 2004-08-17 | 2012-11-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | PDE5 inhibitor composition and method for treating heart disease |
| ES2566774T3 (en) * | 2006-12-13 | 2016-04-15 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivative |
| JP2011505366A (en) | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| IN2015DN02829A (en) | 2011-10-10 | 2015-09-11 | Lundbeck & Co As H | |
| WO2013110768A1 (en) | 2012-01-26 | 2013-08-01 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| JP5842640B2 (en) * | 2012-01-31 | 2016-01-13 | 株式会社東洋新薬 | Phosphodiesterase 3 inhibitor |
| WO2016022836A1 (en) * | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9938284B2 (en) | 2014-08-07 | 2018-04-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112018000254A2 (en) | 2015-07-07 | 2018-09-04 | H Lundbeck As | pde9 inhibitors with imidazotriazinone main chain and imidazopyrazinone main chain for the treatment of peripheral diseases |
| HUE065709T2 (en) | 2018-05-25 | 2024-06-28 | Cardurion Pharmaceuticals Inc | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| DE19510965A1 (en) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation |
-
2000
- 2000-01-14 CZ CZ20012627A patent/CZ20012627A3/en unknown
- 2000-01-14 EP EP00901561A patent/EP1144410A2/en not_active Withdrawn
- 2000-01-14 HU HU0105132A patent/HUP0105132A3/en unknown
- 2000-01-14 SK SK1032-2001A patent/SK10322001A3/en unknown
- 2000-01-14 ID IDW00200101592A patent/ID29790A/en unknown
- 2000-01-14 EA EA200100792A patent/EA200100792A1/en unknown
- 2000-01-14 JP JP2000594808A patent/JP2002535330A/en active Pending
- 2000-01-14 CN CN00805307A patent/CN1344268A/en active Pending
- 2000-01-14 EE EEP200100377A patent/EE200100377A/en unknown
- 2000-01-14 BR BR0007613-9A patent/BR0007613A/en not_active Application Discontinuation
- 2000-01-14 WO PCT/EP2000/000260 patent/WO2000043392A2/en not_active Application Discontinuation
- 2000-01-14 KR KR1020017009112A patent/KR20010101603A/en not_active Application Discontinuation
- 2000-01-14 IL IL14415600A patent/IL144156A0/en unknown
- 2000-01-14 TR TR2001/02121T patent/TR200102121T2/en unknown
- 2000-01-14 AU AU22912/00A patent/AU2291200A/en not_active Abandoned
- 2000-01-19 CA CA002296224A patent/CA2296224A1/en not_active Abandoned
- 2000-01-19 AR ARP000100246A patent/AR022318A1/en unknown
- 2000-01-19 CO CO00002747A patent/CO5190700A1/en not_active Application Discontinuation
-
2001
- 2001-06-29 IS IS5987A patent/IS5987A/en unknown
- 2001-07-05 NO NO20013334A patent/NO20013334D0/en not_active Application Discontinuation
- 2001-07-17 BG BG105714A patent/BG105714A/en unknown
- 2001-07-19 LV LV010109A patent/LV12793B/en unknown
- 2001-07-19 LT LT2001078A patent/LT2001078A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20012627A3 (en) | 2002-01-16 |
| EE200100377A (en) | 2002-10-15 |
| EP1144410A2 (en) | 2001-10-17 |
| TR200102121T2 (en) | 2002-01-21 |
| KR20010101603A (en) | 2001-11-14 |
| JP2002535330A (en) | 2002-10-22 |
| BG105714A (en) | 2002-02-28 |
| CN1344268A (en) | 2002-04-10 |
| AR022318A1 (en) | 2002-09-04 |
| IS5987A (en) | 2001-06-29 |
| IL144156A0 (en) | 2002-05-23 |
| WO2000043392A2 (en) | 2000-07-27 |
| WO2000043392A3 (en) | 2000-09-28 |
| NO20013334L (en) | 2001-07-05 |
| AU2291200A (en) | 2000-08-07 |
| HUP0105132A3 (en) | 2002-12-28 |
| ID29790A (en) | 2001-10-11 |
| LV12793A (en) | 2002-02-20 |
| EA200100792A1 (en) | 2002-10-31 |
| CA2296224A1 (en) | 2000-07-20 |
| LT2001078A (en) | 2002-08-26 |
| LV12793B (en) | 2002-05-20 |
| SK10322001A3 (en) | 2002-07-02 |
| NO20013334D0 (en) | 2001-07-05 |
| HUP0105132A2 (en) | 2002-05-29 |
| BR0007613A (en) | 2001-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5190700A1 (en) | IMIDAZO COMPOUNDS [1,5-a] -PRESS [3,2-e] PIRAZONAS, PROCEDURE FOR PREPARATION AND MEDICINES CONTAINING THEM. . . . . | |
| CR20110380A (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH (DIVISIONAL EXP. 8266) | |
| HRP20050712A2 (en) | SUBSTITUTED HEXAHYDROPYRAZINO[1,2-a]PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | |
| UY27779A1 (en) | CHEMICAL COMPOUNDS | |
| MY120842A (en) | 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use. | |
| Shurpik et al. | Supramolecular neuromuscular blocker inhibition by a pillar [5] arene through aqueous inclusion of rocuronium bromide | |
| UY29277A1 (en) | BENZAMID DERIVATIVES (4 (4- (1-ISOPROPIL-2-METHYL-1H-IMIDAZOL-5-IL) -PIRIMIDIN-2-IL) AMINO) SUBSTITUTES, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURE AND APPLICATIONS | |
| BR0014352A (en) | Spirocyclic ketoenols replaced by trifluoromethyl | |
| RU99121518A (en) | DERIVATIVES 1,5-DIHYDRO-PYRAZOLO [3,4-D] -PYRIMIDINONE | |
| ES2178268T3 (en) | CONTROLLED RELEASE FORMULATIONS. | |
| EA199900303A2 (en) | Carbazol derivatives | |
| UY28733A1 (en) | CHEMICAL COMPOUNDS | |
| PA8632601A1 (en) | PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH | |
| ATE349487T1 (en) | SILVER-BASED POWDER, METHOD FOR PRODUCING THEREOF, AND HARDENABLE SILOXANE COMPOSITION | |
| FI103668B1 (en) | Process for the preparation of pharmacologically active pyrrolo [3,2-e] indole-4 (5H) unidimers | |
| UY26133A1 (en) | SUBSTITUTED DERIVATIVE OF PYRAZOLE. | |
| MX9400070A (en) | HETERO CYCLIC COMPOUNDS, A PROCEDURE TO PREPARE THEM, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| ES2059931T3 (en) | PROCEDURE FOR THE TREATMENT OF HYPERTROPHY AND CARDIAC HYPERPLASIA AS WELL AS VASCULAR. | |
| MX9400253A (en) | DERIVATIVES OF PIPERAZINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| ES2038708T3 (en) | METHOD FOR PRODUCING BENZOTIEPINE (5,4-C) PIRIDAZINE COMPOUNDS. | |
| PE86698A1 (en) | INDOLINA DERIVATIVES | |
| ES2132283T3 (en) | N-HETEROARIL DERIVATIVES SUBSTITUTED FOR PROPANAMIDE USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES. | |
| AR029617A1 (en) | PROCEDURE TO PREPARE SECRETAGOGS OF GROWTH HORMONES AND POLYMORPH OF THE COMPOUNDS OBTAINED | |
| BR0214173A (en) | Process for reacting alkaloids, reaction product, mixture of reaction products, and use of reaction products | |
| ES2153789B1 (en) | PROCEDURE FOR OBTAINING 178- (N-TERC-BUTLCARBAMOIL) -3-ONA-4-AZA-STEROIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |